SABS
NASDAQSAB Biotherapeutics Inc.
Price$3.39-0.54 (-13.74%)
2026-03-042026-06-05
News · 26 weeks60-75%
2025-12-142026-06-07
Mix2790d
- Other10(37%)
- SEC Filings7(26%)
- Offering4(15%)
- Analyst4(15%)
- Insider1(4%)
- Earnings1(4%)
Latest news
25 items- PRSAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual MeetingMIAMI, May 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that it will present data at two congresses in June. SAB BIO will present an oral presentation at the 2026 Scientific Sessions of the American Diabetes Association® (ADA) being held June 5-8, 2026, in New Orleans, LA. The Company will also present a poster presentation at the Federation of Clinical Immunology Societies (FOCIS) 2026 Annual Meeting being held June 9-12, 2026, in San Francisco, CA. Data to be presented will highlight SAB
- ANALYSTCitigroup initiated coverage on SAB BIO with a new price targetCitigroup initiated coverage of SAB BIO with a rating of Buy and set a new price target of $11.00
- ANALYSTJefferies initiated coverage on SAB BIO with a new price targetJefferies initiated coverage of SAB BIO with a rating of Buy and set a new price target of $11.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SAB Biotherapeutics Inc.SCHEDULE 13G/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)
- SECSEC Form SCHEDULE 13G filed by SAB Biotherapeutics Inc.SCHEDULE 13G - SAB Biotherapeutics, Inc. (0001833214) (Subject)
- SECSEC Form SCHEDULE 13G filed by SAB Biotherapeutics Inc.SCHEDULE 13G - SAB Biotherapeutics, Inc. (0001833214) (Subject)
- SECSEC Form 10-Q filed by SAB Biotherapeutics Inc.10-Q - SAB Biotherapeutics, Inc. (0001833214) (Filer)
- PRSAB BIO Reports Q1 2026 Financial Results and Recent Business HighlightsContinued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027 Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities Conference call today at 8:30 AM ET MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human an
- PRSAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ETMIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its first quarter 2026 financial results will be issued in the morning of Tuesday, May 12, 2026. Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide business updates. To access the live conference call, participants may register here. Conference Details: Conference Date: Tuesday, May 12, 2026Conference Time: 8:30 AM ETConference Dial-in: 1-877-704-4453International Dial-in: 1-201
- SECSAB Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)
- SECSEC Form SCHEDULE 13G filed by SAB Biotherapeutics Inc.SCHEDULE 13G - SAB Biotherapeutics, Inc. (0001833214) (Subject)
- SECSEC Form DEF 14A filed by SAB Biotherapeutics Inc.DEF 14A - SAB Biotherapeutics, Inc. (0001833214) (Filer)
- PREmergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (NASDAQ:SABS, SAB BIO)) to support the process development and manufacturing of SAB-142, SAB BIO's lead program in clinical development for autoimmune type 1 diabetes (T1D). The executed agreement is valued at approximately $50 million, of which $36 million is contingent on future regulatory approval and downstream milestones. Under the terms of the agreement, Emergent will provide end-to-end development and manufacturing services to SAB BIO that are compliant with current good manufacturing practices. These services will includ
- SECSAB Biotherapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)
- PRSAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder profile concomitant with T cell exhaustion T1D participants receiving SAB-142 showed improved glycemic control MIAMI, April 22, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today presented additional clinical and mechanistic data from the Phase 1 HUman anti-thymocyte biologic in first-in-MAN (HUMAN) clinical trial of SAB-142 at the 21st Immunology of Diabetes Society (IDS) Congress in
- PRSAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society CongressMIAMI, April 15, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company will give an oral presentation and multiple poster presentations at the 21st Immunology of Diabetes Society (IDS) Congress being held April 20-24, 2026, in Brisbane, Australia. Data to be presented will highlight SAB BIO's lead program, SAB-142, a potentially best-in-class, disease-modifying, redosable immunotherapy in clinical development for newly diagnosed Stage 3 T1D patients. Alexandra Kropotova, M.D., MBA, Chi
- ANALYSTRodman & Renshaw initiated coverage on SAB BIO with a new price targetRodman & Renshaw initiated coverage of SAB BIO with a rating of Buy and set a new price target of $13.00
- ANALYSTRodman & Renshaw initiated coverage on SAB BIO with a new price targetRodman & Renshaw initiated coverage of SAB BIO with a rating of Buy and set a new price target of $13.00
- SECSEC Form S-8 filed by SAB Biotherapeutics Inc.S-8 - SAB Biotherapeutics, Inc. (0001833214) (Filer)
- INSIDERSEC Form 4 filed by Kropotova Alexandra4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by SAB Biotherapeutics Inc.SCHEDULE 13D/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)
- PRSAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsMIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the closing of an underwritten public offering of 19,324,677 shares of its common stock at a public offering price of $3.85 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 2,753,246 shares of common stock at a public offering price of $3.8499 per pre-funded warrant, which represents the per share public offering price less the $0.0001 per share exercise price for each pre-funded war
- PRSAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsMIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the pricing of an underwritten public offering of 19,324,677 shares of its common stock at a public offering price of $3.85 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 2,753,246 shares of common stock at a public offering price of $3.8499 per pre-funded warrant, which represents the per share public offering price less the $0.0001 per share exercise price for each pre-funded war
- SECSEC Form 424B5 filed by SAB Biotherapeutics Inc.424B5 - SAB Biotherapeutics, Inc. (0001833214) (Filer)
- PRSAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsMIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that it has commenced an underwritten public offering of shares of its common stock (and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock). SAB BIO also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the of the securities to be sold in the proposed offering at the public offering price, less underwriting discounts and commissions. All of th
SABS FAQ
7 questionsWhat does SAB Biotherapeutics Inc. do?
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic for the treatment of COVID-19 advancing as part of the NIH's ACTIV-2 protocol; and SAB-176, a fully-human polyclonal antibody therapeutic candidate designed to bind to type A and B viruses. The company's pre-clinical product...Where does SABS stock trade?
SAB Biotherapeutics Inc. (SABS) is listed on NASDAQ.What sector and industry is SABS in?
SAB Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did SAB Biotherapeutics Inc. go public?
SAB Biotherapeutics Inc. (SABS) completed its IPO in 2021.What are analysts saying about SABS?
SAB Biotherapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy with a $1100.00 price target on 2026-05-22. Recent price targets range from $700.00 to $1500.00.What companies are similar to SABS?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare SABS side-by-side with any of them on Quantisnow.How can I track SABS on Quantisnow?
Quantisnow aggregates SAB Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SABS to receive live email and push alerts on every new disclosure.